Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous genetically-modified MAGE-A4 C1032 CD8alpha T cells

Autologous human T lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4) and the CD8alpha co-receptor, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous genetically-modified MAGE-A4 C1032 CD8alpha T cells bind to tumor cells expressing MAGE-A4. This may result in both inhibition of growth and increased cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T cells into CD8+ cytotoxic T cells.
Synonym:ADP-A2M4CD8
autologous genetically-modified MAGE-A4 C1032 CD8alpha T lymphocytes
autologous genetically-modified melanoma antigen A4 CD8alpha T cells
autologous MAGE-A4 C1032 TCR-modified CD8alpha T cells
autologous TCR-transduced MAGE-A4 C1032 CD8alpha T cells
MAGE-A4 SPEAR CD8alpha T cells
MAGE-A4 SPEAR CD8alpha T-cells
MAGE-A4-specific TCR gene-transduced C1032 CD8alpha T lymphocytes
MAGE-A4-specific TCR gene-transduced C1032 CD8alpha T-lymphocytes
SPEAR T-cell ADP-A2M4CD8
Search NCI's Drug Dictionary